NCT05133297View on ClinicalTrials.gov

The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

February 16, 2022

Primary Completion Date

December 19, 2022

Study Completion Date

May 30, 2023

Conditions
Rheumatoid Arthritis
Interventions
DRUG

TLL-018

Oral tablets administered at dose1 BID daily for 24 weeks.

DRUG

TLL-018

Oral tablets administered at dose2 BID daily for 24 weeks.

DRUG

TLL-018

Oral tablets administered at dose3 BID daily for 24 weeks.

DRUG

Tofacitinib

Oral tablets administered at 5 mg BID daily for 24 weeks.

Trial Locations (1)

100000

Peking Union Medical College Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Hangzhou Highlightll Pharmaceutical Co., Ltd

INDUSTRY